Across TCGA pan-cancer cohorts, PRSS46P Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated PRSS46P data layer compared with 21 for mass-spec protein.
The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher PRSS46P Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated PRSS46P expression acts as an unfavorable survival marker.
CESC are the cancer types where PRSS46P Mutation most reproducibly stratifies survival.